XML 76 R62.htm IDEA: XBRL DOCUMENT v3.25.0.1
ALLIANCES - Financial Information Pertaining to Alliances (Pfizer) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Alliance Statement [Line Items]      
Total Revenues $ 48,300 $ 45,006 $ 46,159
Cost of products sold – profit sharing [1] 13,968 10,693 10,137
Other (income)/expense, net 893 (1,158) 576
Receivables 10,747 10,921  
Accounts payable 3,602 3,259  
Net product sales      
Alliance Statement [Line Items]      
Total Revenues 46,778 43,778 44,671
Eliquis      
Alliance Statement [Line Items]      
Total Revenues 13,333 12,206 11,789
Pfizer      
Alliance Statement [Line Items]      
Total Revenues 13,333 12,206 11,789
Alliance revenues      
Alliance Statement [Line Items]      
Total Revenues 14,066 13,151 12,743
Cost of products sold – profit sharing 6,597 6,067 5,768
Other (income)/expense, net (137) (49) (53)
Receivables 221 233  
Accounts payable 1,578 1,394  
Deferred income 222 274  
Alliance revenues | Net product sales      
Alliance Statement [Line Items]      
Total Revenues 13,587 12,543 12,001
Alliance revenues | Pfizer      
Alliance Statement [Line Items]      
Total Revenues 146 200 301
Cost of products sold – profit sharing 6,419 5,833 5,604
Other (income)/expense, net (42) (42) (42)
Receivables 189 169  
Accounts payable 1,463 1,311  
Deferred income 137 180  
Alliance revenues | Pfizer | Net product sales      
Alliance Statement [Line Items]      
Total Revenues $ 13,187 $ 12,006 $ 11,488
Alliance revenues | Pfizer | Eliquis | Minimum      
Alliance Statement [Line Items]      
Percentage of reimbursement for development costs from alliance partner 50.00%    
Alliance revenues | Pfizer | Eliquis | Maximum      
Alliance Statement [Line Items]      
Percentage of reimbursement for development costs from alliance partner 60.00%    
[1] Excludes amortization of acquired intangible assets.